Скачать или смотреть Engineering T-cell engagers with complete killing selectivity

This talk, “Engineering T-cell engagers with complete killing selectivity through the closed-loop integration of ML and high-throughput experimentation” was given during the 2024 PEGS Europe conference in Barcelona, Spain by Dr. James Field, CEO of LabGenius, a next-generation antibody discovery company. LabGenius has pioneered the development of an ML-driven antibody engineering platform that’s capable of designing, conducting and, critically, learning from its own experiments.
T-cell engagers (TCEs) promise breakthroughs in the treatment of solid tumors but their progression in the clinic has been limited by on-target, off-tumor toxicity. In this talk, Dr. James Field describes how LabGenius’ platform combines high-throughput cell-based functional assays with ML to identify highly potent TCEs with switch-like killing selectivity for tumor cells.